WMJ : official publication of the State Medical Society of Wisconsin · 2026
De Novo Hepatocellular Carcinoma in Primary Sclerosing Cholangitis Post-Liver Transplant: The Case for Surveillance.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Frie Anneleise, Said Adnan
Аннотация
INTRODUCTION: While recurrent primary sclerosing cholangitis and de novo malignancies such as skin cancer are common after liver transplantation, de novo hepatocellular carcinoma (HCC) after liver transplantation for primary sclerosing cholangitis is exceedingly rare.
CASE PRESENTATION: A 72-year-old man with ulcerative colitis underwent liver transplantation for primary sclerosing cholangitis. Thirty years later, abdominal imaging incidentally revealed cirrhotic liver morphology with a new, bulky, and locally invasive hepatic mass. Biopsy confirmed stage IIIA hepatocellular carcinoma, which was treated successfully with Y-90 radioembolization segmentectomy.
DISCUSSION: Immunosuppression-related malignancies are prevalent in long-term liver transplant survivors, and HCC recurrence can occur in patients transplanted for HCC. However, de novo HCC is rare in liver transplant recipients with primary sclerosing cholangitis and has primarily been reported in patients with viral hepatitis.
CONCLUSIONS: Vigilant screening for allograft fibrosis, cirrhosis, and malignancy using emerging modalities in long-time liver transplant survivors warrants consideration.
CASE PRESENTATION: A 72-year-old man with ulcerative colitis underwent liver transplantation for primary sclerosing cholangitis. Thirty years later, abdominal imaging incidentally revealed cirrhotic liver morphology with a new, bulky, and locally invasive hepatic mass. Biopsy confirmed stage IIIA hepatocellular carcinoma, which was treated successfully with Y-90 radioembolization segmentectomy.
DISCUSSION: Immunosuppression-related malignancies are prevalent in long-term liver transplant survivors, and HCC recurrence can occur in patients transplanted for HCC. However, de novo HCC is rare in liver transplant recipients with primary sclerosing cholangitis and has primarily been reported in patients with viral hepatitis.
CONCLUSIONS: Vigilant screening for allograft fibrosis, cirrhosis, and malignancy using emerging modalities in long-time liver transplant survivors warrants consideration.